Professor of Human Anatomy at the State University of Campinas (UNICAMP) and specialist in Uropathology, Urogenital Carcinogenesis, Nanomedicine and Drug Development. He holds a Masters, Doctorate and Post-Doctorate degrees from UNICAMP. He is an international member of the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Founding Partner of NANOIMMUNOTHERAPY PHARMA LTDA, a company dedicated to the development of medicines for human and veterinary use. He has published several scientific articles in national and international journals with a selective editorial policy, as well as book chapters. It has patents filed in Brazil and abroad and registered trademarks, with emphasis on the development process of the OncoTherad immunotherapy. He is on the Top 10,000 list of Latin America's Most Influential Researchers by the Alper-Doger (AD) Scientific Index 2021. He has received numerous awards for his scientific contribution, including the UNICAMP 2020 Inventors Award in the Licensed Technology and Spin-Off Creation categories; "Newton Prado" Medal (2018) for relevant services rendered to the community; Prof. Nelson Rodrigues Netto Jr. of Urology (2018) and; INOVA UNICAMP Award for Initiation to Innovation (2018); in addition to several awards at scientific events. After 15 years of research into urogenital carcinogenesis and nanotechnology, he developed the first 100% Brazilian immunotherapy within a public university. Immunotherapy named OncoTherad (MRB-CFI-1) has been shown to have great potential in reducing different solid tumors. As a result of pre-clinical and clinical studies, in animals and humans, of OncoTherad immunotherapy (MRB-CFI-1), Dr. Wagner José Fávaro created the Center for Immunotherapy and Inflammatory Diseases (CIDI)/UNICAMP, acting as coordinator general. He coordinated the International Cooperation in Research and Development Project by the Ministry of Science, Technology, Innovation and Communications (MCTIC) with Slovenia (2014). He was the main representative of the Ministry of Science and Technology (MCTI) at the Consortium Brazil European Community, called NANoREG (The common European approach to regulatory testing of Manufactured Nanomaterials) for the establishment of assessment protocols for nanomaterials. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Mensajeros poderosos |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Bladder cancer (BC) represents the second most common malignant disease of the urinary tract, and one of the neoplasms that have the highest costs for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on surgical treatment using transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to redu…
Bladder cancer (BC) is the second most common malignant disease of the urinary tract, and one of the most costly neoplasms for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to decrease recurrence and prevent tumor progression. Ho…
Understanding how cancer cells are able to ensure a positive energetic balance and associate it with anabolic processes is vital to the development of effective therapies against cancer. The neoplastic cells face two major challenges: answer the bioenergetic and biosynthetic demands of increased growth and cellular proliferation and implement metabolic adaptation strategies to survive the…
(Only some records are available in English at this moment)
Bacillus Calmette-Guerin (BCG) immunotherapy is the most effective form of intravesical therapy for the prophylaxis of recurrence and progression of non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is often associated with local and/or systemic adverse effects, including sepsis, in addition to tumor recurrence in up to 40% of cases. The incidence of these effects is …
In Brazil ovarian cancer is the seventh most common cancer in the Midwest, Northeast and North regions, and the eighth most common in women in the South and Southeast regions. In Brazil, approximately 6150 new cases are estimated between 2018 and 2019, with an estimated risk of 5.79 cases per 100,000 women. The average age of women with these tumors is 60 years, and the risk of developing…
Stretch marks are common skin lesions, resulting from stretching or distension of the skin, due to the rupture of elastic and collagen fibers. Its treatment is quite challenging, whether in the prophylactic or preventive form and so far, no therapy is sufficiently effective and with minimal adverse effects. In this sense, it is necessary to develop new therapeutic approaches for the treat…
Nearly half a century the immunotherapy with Bacillus Calmette-Guerin (BCG) has been the gold standard treatment for non-muscle invasive bladder cancer (NMIBC). However, many patients with high-risk disease experience recurrence, including those who progress and eventually become unresponsive to BCG. For decades, apart from radical cystectomy, few therapeutic options existed for this at-r…
Bladder cancer (BC) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. As the overall prognosis of BC has not changed over the past 30 years, there is a pressing medical need to develop new diagnostic and therapeutic approaches. Bacillus Calmette-Guerin (BCG) immunotherapy is the most effective form of intravesical therapy for the prophylax…
(Only some records are available in English at this moment)
Ovarian cancer (OC) ranks fifth among cancer deaths in women and remains the deadliest of all gynecological cancers. The OC poor outcomes highlight the need to develop new clinical approaches and especially a better understanding of this disease. Molecular analyzes have shown significant genetic heterogeneity among the OC subtypes and the importance of an assessment of underlying molecula…
| 5 / 5 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 34 / 32 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 42 / 40 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID